Adverse effects of heparin.

All the adverse effects of heparins are related to their wide variety of biological activities, with bleeding being the most important safety issue, resulting directly from the potency of heparin as an anticoagulant. However, it is hard to define the bleeding risk, since it depends on numerous parameters including the indication, dosage, method, and duration of heparin application, the clinical study design and definition of bleeding as well as patient characteristics and determinants of bleeding such as type of surgery and co-medication. Nonbleeding complications of heparins are caused by binding of heparin molecules to proteins other than antithrombin and to cells, which is generally more pronounced with unfractionated heparin than with low-molecular-weight heparins. Accordingly, heparin-induced thrombocytopenia, the most severe nonbleeding adverse reaction, occurs about 10 times less with low-molecular-weight heparins than with unfractionated heparin. Frequent and therefore important adverse reactions of heparins are skin lesions resulting from delayed-type hypersensitivity reactions. All the other undesirable effects are discussed as well, but they are mostly clinically irrelevant.

[1]  E. Bröcker,et al.  Tolerance to intravenous heparin in patients with delayed‐type hypersensitivity to heparins: a prospective study , 2005, British journal of haematology.

[2]  W. Fraser,et al.  Prospective observational study of bone mineral density during pregnancy: low molecular weight heparin versus control. , 2004, Human reproduction.

[3]  R. Beyth,et al.  Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[4]  J. Herbert,et al.  Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. , 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[5]  M. J. Hursting,et al.  Reducing Harm Associated with Anticoagulation , 2009, Drug safety.

[6]  A. Greinacher,et al.  Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation , 2005, Thrombosis and Haemostasis.

[7]  M. Monreal,et al.  Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia , 2004, European Journal of Clinical Pharmacology.

[8]  L. Alberio Heparin-induced thrombocytopenia: some working hypotheses on pathogenesis, diagnostic strategies and treatment , 2008, Current opinion in hematology.

[9]  O. Reikerås,et al.  Preoperative versus Postoperative Initiation of Dalteparin Thromboprophylaxis in THA , 2010 .

[10]  E. Ohman,et al.  Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. , 1998, Chest.

[11]  M. Poncz,et al.  Immune Vascular Injury in Heparin- Induced Thrombocytopenia , 2003 .

[12]  I. Greer,et al.  Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. , 2005, Blood.

[13]  J. Hirsh,et al.  Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. , 2005, Chest.

[14]  Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. , 1991 .

[15]  O. Hélénon,et al.  Randomized Trial of Subcutaneous Low‐Molecular‐Weight Heparin CY 216 (Fraxiparine) Compared With Intravenous Unfractionated Heparin in the Curative Treatment of Submassive Pulmonary Embolism: A Dose‐Ranging Study , 1992, Circulation.

[16]  P. Wells,et al.  Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. , 2009, Thrombosis research.

[17]  M. Alhenc-Gelas,et al.  Adjusted Versus Fixed Doses of the Low-Molecular-Weight Heparin Fragmin in the Treatment of Deep Vein Thrombosis , 1994, Thrombosis and Haemostasis.

[18]  R. Aster,et al.  Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4. , 1998, Blood.

[19]  M. Schindewolf,et al.  Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides , 2005, Thrombosis and Haemostasis.

[20]  T. Kohlmann,et al.  The temporal profile of the anti-PF4/heparin immune response. , 2009, Blood.

[21]  T. Warkentin,et al.  Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists. , 1999, Platelets.

[22]  S. Alban [Natural and synthetic glycosaminoglycans. Molecular characteristics as the basis of distinct drug profiles]. , 2008, Hamostaseologie.

[23]  B. Eriksson,et al.  Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. , 2005, Blood.

[24]  W. Weitschies,et al.  Close Approximation of Two Platelet Factor 4 Tetramers by Charge Neutralization Forms the Antigens Recognized by HIT Antibodies , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[25]  A. Greinacher,et al.  Role of Sulfated Polysaccharides in the Pathogenesis of Heparin- Induced Thrombocytopenia , 2003 .

[26]  A. Chernoff Anaphylactic reaction following injection of heparin. , 1950, The New England journal of medicine.

[27]  J H Lewis,et al.  Drug-induced liver disease. , 2000, Clinics in liver disease.

[28]  I. Greer,et al.  Low molecular weight heparin in pregnancy: current issues , 2005, British journal of haematology.

[29]  P. Wells,et al.  Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. , 2005, Blood.

[30]  R. Apsner,et al.  Dalteparin-induced alopecia in hemodialysis patients: reversal by regional citrate anticoagulation. , 2001, Blood.

[31]  C. Schizas,et al.  The effect of anticoagulant pharmacotherapy on fracture healing , 2008, Expert opinion on pharmacotherapy.

[32]  P. Itin,et al.  Delayed hypersensitivity to one low‐molecular‐weight heparin with tolerance of other low‐molecular‐weight heparins , 1995, The British journal of dermatology.

[33]  B. Chong,et al.  Heparin-induced Thrombocytopenia: Towards Consensus , 1998, Thrombosis and Haemostasis.

[34]  W. Aberer,et al.  Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight. Commentary. , 2007 .

[35]  S. Sakamoto,et al.  Early onset of immunological heparin‐induced thrombocytopenia in acute myocardial infarction , 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[36]  W. Aberer,et al.  Acute generalized exanthematous pustulosis from dalteparin. , 2007, Journal of the American Academy of Dermatology.

[37]  M. Butcher,et al.  The effects of heparin and low molecular weight heparins on bone. , 2008, Thrombosis research.

[38]  S Alban,et al.  Pharmacological strategies for inhibition of thrombin activity. , 2008, Current pharmaceutical design.

[39]  L. Kaklamanis,et al.  Diffuse alopecia in a hemodialysis patient caused by a low-molecular-weight heparin, tinzaparin. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[40]  S. Frostick,et al.  Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial , 2007, Journal of thrombosis and haemostasis : JTH.

[41]  A. Bircher,et al.  Immediate type hypersensitivity to low molecular weight heparins and tolerance of unfractioned heparin and fondaparinux , 2006, Allergy.

[42]  W. Fry,et al.  HEPARIN REACTIONS IN PATIENTS WITH VASCULAR DISEASE. , 1965, Archives of surgery.

[43]  W. Aberer,et al.  Delayed-type skin reaction to the heparin-alternative danaparoid. , 2000, Journal of the American Academy of Dermatology.

[44]  Lijuan Zhang,et al.  Molecular mechanism underlines heparin-induced thrombocytopenia and thrombosis. , 2010, Progress in molecular biology and translational science.

[45]  K. Alexander,et al.  Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. , 2005, JAMA.

[46]  R. W. Meikle,et al.  Alopecia following Treatment with Dextran Sulphate and Other Anticoagulant Drugs , 1958, British medical journal.

[47]  Michael Weis,et al.  Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. , 2008, European heart journal.

[48]  B. Dahlbäck,et al.  The multiple faces of the partial thromboplastin time APTT , 2004, Journal of thrombosis and haemostasis : JTH.

[49]  R. Hull,et al.  Antithrombotic therapy for venous thromboembolic disease. , 1986, Chest.

[50]  Y. Gruel,et al.  Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. , 2001 .

[51]  A. Disch,et al.  Effects of Fondaparinux Compared with Dalteparin, Enoxaparin and Unfractionated Heparin on Human Osteoblasts , 2003, Calcified Tissue International.

[52]  A. Bircher,et al.  Delayed‐type hypersensitivity to the ultra‐low‐molecular‐weight heparin fondaparinux , 2004, Contact dermatitis.

[53]  R. Paus Hair growth inhibition by heparin in mice: a model system for studying the modulation of epithelial cell growth by glycosaminoglycans? , 1991, The British journal of dermatology.

[54]  P. Prandoni,et al.  Predicting recurrences or major bleeding in cancer patients with venous thromboembolism , 2008, Thrombosis and Haemostasis.

[55]  M. Takami,et al.  Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. , 2007, Bone.

[56]  E. Lindhoff‐Last,et al.  Hirudin determination in plasma can be strongly influenced by the prothrombin level. , 2000, Thrombosis research.

[57]  M. Monreal,et al.  Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry , 2008, Thrombosis and Haemostasis.

[58]  A. Pisciotta,et al.  ALOPECIA AND OTHER TOXIC EFFECTS OF HEPARIN AND SYNTHETIC HEPARINOIDS , 1954, The American journal of the medical sciences.

[59]  G. Sacchi,et al.  Protective effects of heparin on hepatic ischemia and reperfusion lesions in rabbits. , 2009, Transplantation proceedings.

[60]  P. Miller Guidelines for the diagnosis of osteoporosis: T-scores vs fractures , 2007, Reviews in Endocrine and Metabolic Disorders.

[61]  G. Raskob,et al.  Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[62]  A. Cohen,et al.  Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction). , 2014, The Cochrane database of systematic reviews.

[63]  J. Hirsh,et al.  A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. , 1997, Blood.

[64]  S. Kahn,et al.  Long‐term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial , 2007, Journal of thrombosis and haemostasis : JTH.

[65]  J. Kelton,et al.  A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. , 2008, The American journal of medicine.

[66]  B. Lobo,et al.  Fondaparinux for the treatment of patients with acute heparininduced thrombocytopenia , 2007, Thrombosis and Haemostasis.

[67]  G. Wanner,et al.  Cbfa-1 (Runx-2) and Osteocalcin Expression by Human Osteoblasts in Heparin Osteoporosis in Vitro , 2006, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[68]  S. MacIsaac,et al.  Low-molecular-weight heparin prophylaxis: preoperative versus postoperative initiation in patients undergoing elective hip surgery. , 2001, Thrombosis research.

[69]  Salim Yusuf,et al.  Relationship of Activated Partial Thromboplastin Time to Coronary Events and Bleeding in Patients With Acute Coronary Syndromes Who Receive Heparin , 2003, Circulation.

[70]  V. Hiilesmaa,et al.  Postpartum Bone Mineral Density in Women Treated for Thromboprophylaxis with Unfractionated Heparin or LMW Heparin , 2002, Thrombosis and Haemostasis.

[71]  U. Jappe Allergy to heparins and anticoagulants with a similar pharmacological profile: an update , 2006, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[72]  A. Trautmann,et al.  The complex clinical picture of side effects to anticoagulation. , 2010, The Medical clinics of North America.

[73]  N. Heddle,et al.  Laboratory diagnosis of immune heparin-induced thrombocytopenia. , 2003, Current hematology reports.

[74]  M. Bhandari,et al.  A histomorphometric evaluation of heparin-induced bone loss after discontinuation of heparin treatment in rats. , 1999, Blood.

[75]  L. Rauova,et al.  Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. , 2005, Blood.

[76]  T. Ortel,et al.  Heparin-induced thrombocytopenia. , 2006, Seminars in hematology.

[77]  C. Christiansen Osteoporosis: diagnosis and management today and tomorrow. , 1995, Bone.

[78]  M. Rodger,et al.  Heparin-induced osteoporosis and pregnancy , 2008, Current opinion in pulmonary medicine.

[79]  B. Eriksson,et al.  Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. , 2002, Archives of internal medicine.

[80]  M. Monreal,et al.  Comparison of Subcutaneous Unfractionated Heparin with a Low Molecular Weight Heparin (Fragmin®) in Patients with Venous Thromboembolism and Contraindications to Coumarin , 1994, Thrombosis and Haemostasis.

[81]  T. Warkentin Agents for the treatment of heparin-induced thrombocytopenia. , 2010, Hematology/oncology clinics of North America.

[82]  J. Philippé,et al.  A clinical-laboratory approach contributing to a rapid and reliable diagnosis of heparin-induced thrombocytopenia. , 2008, Thrombosis research.

[83]  G. Arepally,et al.  Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. , 2001, Blood.

[84]  V. Marder,et al.  Anti‐PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non‐drug risk factors and evidence for a stoichiometry‐based model of immunization , 2010, Journal of thrombosis and haemostasis : JTH.

[85]  R. Bergemann,et al.  Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for thrombo-embolism prophylaxis in orthopaedic surgery: a meta-analysis of randomised clinical trials. , 1997, Haemostasis.

[86]  M. Schindewolf,et al.  Need for an increasing awareness for heparin-induced skin lesions , 2010 .

[87]  J. Utikal,et al.  Management of cutaneous type IV hypersensitivity reactions induced by heparin , 2006, Thrombosis and Haemostasis.

[88]  J. Corson,et al.  Efficacy and Safety of Low Molecular Weight Heparin (Ardeparin Sodium) Compared to Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement Surgery: A Double-blind, Dose-ranging Study , 1997, Thrombosis and Haemostasis.

[89]  C. Sigouin,et al.  Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin‐induced thrombocytopenia in two clinical settings , 2006, Journal of thrombosis and haemostasis : JTH.

[90]  Clifford W Colwell,et al.  Prevention of Venous Thromboembolism* American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition) , 2008 .

[91]  H. Riess,et al.  Blood Coagulation , Fibrinolysis and Cellular Haemostasis 252 Fixed-dose , body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis , 2003 .

[92]  B. Eriksson,et al.  Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacement , 2006, Journal of thrombosis and haemostasis : JTH.

[93]  A. Bircher,et al.  Hypersensitivity reactions to anticoagulant drugs. , 2008, Current pharmaceutical design.

[94]  I. Marzi,et al.  Low allergenic potential with fondaparinux: results of a prospective investigation. , 2010, Mayo Clinic proceedings.

[95]  J. Douketis,et al.  The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[96]  K. Alexander,et al.  Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes. , 2008, American heart journal.

[97]  D. Bergqvist Low molecular weight heparin for the prevention of venous thromboembolism after abdominal surgery , 2004, The British journal of surgery.

[98]  P. Koch,et al.  Delayed-type hypersensitivity skin reactions caused by subcutaneous unfractionated and low-molecular-weight heparins: tolerance of a new recombinant hirudin. , 2000, Journal of the American Academy of Dermatology.

[99]  A. Greinacher,et al.  The direct thrombin inhibitor hirudin , 2008, Thrombosis and Haemostasis.

[100]  T. Dahlman,et al.  Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. , 1993, American journal of obstetrics and gynecology.

[101]  J. Hirsh,et al.  Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. , 1996, Blood.

[102]  M. Prins,et al.  Once versus twice daily LMWH for the initial treatment of venous thromboembolism. , 2002, The Cochrane database of systematic reviews.

[103]  M. Haugh,et al.  Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. , 1993, Haemostasis.

[104]  T. Warkentin,et al.  Heparin‐induced thrombocytopenia: pathogenesis and management , 2003, British journal of haematology.

[105]  T. Kohlmann,et al.  Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis , 2005, Thrombosis and Haemostasis.

[106]  S. Goldhaber,et al.  Anticoagulants and Transaminase Elevation , 2006, Circulation.

[107]  A. Greinacher,et al.  Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes , 2009, Expert opinion on drug safety.

[108]  J. Kelton,et al.  Temporal aspects of heparin-induced thrombocytopenia. , 2001, The New England journal of medicine.

[109]  P. Stein,et al.  Incidence of thrombocytopenia in hospitalized patients with venous thromboembolism. , 2009, The American journal of medicine.

[110]  T. Burnakis,et al.  Transaminase elevations in patients receiving bovine or porcine heparin. , 1984, Annals of internal medicine.

[111]  F. Dentali,et al.  Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency , 2006, Annals of Internal Medicine.

[112]  A. Bircher,et al.  Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options , 2006, Allergy.

[113]  J. Ansell,et al.  Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change , 2009, Current opinion in hematology.

[114]  B. Chong,et al.  Plasma P-selectin is increased in thrombotic consumptive platelet disorders , 1994 .

[115]  T. Warkentin Think of HIT. , 2006, Hematology. American Society of Hematology. Education Program.

[116]  E. Frenkel,et al.  Clinical Aspects of Heparin-Induced Thrombocytopenia and Thrombosis and other Side Effects of Heparin Therapy , 1999, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[117]  M. Schindewolf,et al.  The influence of heparin’s molecular weight and the incidence of delayed type hypersensitivity reactions revisited; in response to Grims et al., Br J Dermatol 2007; 157:514–17 , 2008, The British journal of dermatology.

[118]  Barbara Mulloy,et al.  Heparin - A Century of Progress , 2012, Handbook of Experimental Pharmacology.

[119]  J. Labarca,et al.  Heparin-induced transaminase elevations: a prospective study. , 1993, International journal of clinical pharmacology, therapy, and toxicology.

[120]  J. Hirsh Heparin and low-molecular weight heparins , 1992 .

[121]  V. Kakkar,et al.  Efficacy and safety of two regimens of low molecular weight heparin fragment (Fragmin) in preventing postoperative venous thrombolism. , 1986, Haemostasis.

[122]  Y. Shoenfeld,et al.  Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. , 2002, International immunology.

[123]  J. Hirsh,et al.  The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. , 1995, Blood.

[124]  L. Lopez Low‐Molecular‐Weight Heparins Are Essentially the Same for Treatment and Prevention of Venous Thromboembolism , 2001, Pharmacotherapy.

[125]  T. Warkentin Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT) – Bridging the River Coumarin , 2007, Thrombosis and Haemostasis.

[126]  T. Kohlmann,et al.  Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. , 2006, Blood.

[127]  I. Ng,et al.  Low Molecular Weight Heparin‐Induced Liver Toxicity , 2001, Journal of clinical pharmacology.

[128]  T. Warkentin,et al.  Non‐necrotizing heparin‐induced skin lesions and the 4T’s score , 2010, Journal of thrombosis and haemostasis : JTH.

[129]  William Wijns,et al.  [Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]. , 2007, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[130]  H. Bounameaux,et al.  Duration of anticoagulation therapy for venous thromboembolism. , 2008, Hematology. American Society of Hematology. Education Program.

[131]  G. Wanner,et al.  Low molecular weight heparin-induced skin necrosis—a systematic review , 2005, Langenbeck's Archives of Surgery.

[132]  T. Warkentin Clinical picture of heparin-induced thrombocytopenia , 2012 .

[133]  D. Moher,et al.  Heparin versus placebo for acute coronary syndromes. , 2008, The Cochrane database of systematic reviews.

[134]  C. Nelson-Piercy Hazards of heparin: allergy, heparin-induced thrombocytopenia and osteoporosis. , 1997, Bailliere's clinical obstetrics and gynaecology.

[135]  G. Guyatt,et al.  The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. , 2010, Journal of critical care.

[136]  P. Monagle,et al.  Alopecia and dalteparin: a previously unreported association. , 2000, Blood.

[137]  J. Kelton,et al.  Heparin-induced thrombocytopenia: a historical perspective. , 2008, Blood.

[138]  E. Ohman,et al.  Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. , 2001, Chest.

[139]  J. Low,et al.  Timely diagnosis and management of heparin‐induced thrombocytopenia in a frequent request, low incidence single centre using clinical 4T’s score and particle gel immunoassay , 2008, British journal of haematology.

[140]  M. Khamashta,et al.  Review: Low-molecular-weight heparin-induced osteoporosis and osteoporotic fractures: A myth or an existing entity? , 2010, Lupus.

[141]  A. Greinacher,et al.  Heparin‐induced thrombocytopenia: a prospective study on the incidence, platelet‐activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes , 2007, Journal of thrombosis and haemostasis : JTH.

[142]  M. Uchiba,et al.  Dalteparin, a low molecular weight heparin, attenuates inflammatory responses and reduces ischemia-reperfusion–induced liver injury in rats* , 2006, Critical care medicine.

[143]  P. Haentjens Thromboembolic prophylaxis in orthopaedic trauma patients: a comparison between a fixed dose and an individually adjusted dose of a low molecular weight heparin (nadroparin calcium) , 1996, Injury.

[144]  J. Kelton,et al.  Studies of the immune response in heparin-induced thrombocytopenia. , 2009, Blood.

[145]  E. Moore,et al.  Case study: contamination of heparin with oversulfated chondroitin sulfate. , 2012, Handbook of experimental pharmacology.

[146]  H. Ackermann,et al.  Heparin‐induced non‐necrotizing skin lesions: rarely associated with heparin‐induced thrombocytopenia , 2010, Journal of thrombosis and haemostasis : JTH.

[147]  I. Bernstein Anaphylaxis to heparin sodium; report of a case, with immunologic studies. , 1956, Journal of the American Medical Association.

[148]  M. Nauck,et al.  The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. , 2010, Blood.

[149]  V. Pettilä,et al.  Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. , 1999, Thrombosis research.

[150]  P. Watkins,et al.  Are patients with elevated liver tests at increased risk of drug-induced liver injury? , 2004, Gastroenterology.

[151]  T. Kohlmann,et al.  Heparin‐induced thrombocytopenia – therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4–heparin complexes , 2008, Journal of thrombosis and haemostasis : JTH.

[152]  J. Hansen,et al.  Liver sinusoidal endothelial cells are the principal site for elimination of unfractionated heparin from the circulation. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[153]  T. Warkentin Heparin‐induced skin lesions , 1996, British journal of haematology.

[154]  A. Greinacher,et al.  Heparin‐induced thrombocytopenia , 2009, Journal of thrombosis and haemostasis : JTH.

[155]  J. Hansen,et al.  Heparin induces mobilization of osteoprotegerin into the circulation , 2007, Thrombosis and Haemostasis.

[156]  S. Hoerstrup,et al.  Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra®) on human osteoblasts in vitro , 2005, The British journal of surgery.

[157]  P. Lips,et al.  Effects of short-term low-dose heparin administration on biochemical parameters of bone turnover. , 1993, Bone and mineral.

[158]  J. Hirsh,et al.  Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[159]  C. Colwell,et al.  Prevention of venous thromboembolism. , 1994, Chest.

[160]  J. Kelton,et al.  The Pathogenesis of Venous Limb Gangrene Associated with Heparin-Induced Thrombocytopenia , 1997, Annals of Internal Medicine.

[161]  L. Rauova,et al.  Heparin‐induced thrombocytopenia: An autoimmune disorder regulated through dynamic autoantigen assembly/disassembly , 2007, Journal of clinical apheresis.

[162]  J. Eikelboom,et al.  Bleeding Complications in Acute Coronary Syndromes and Percutaneous Coronary Intervention: Predictors, Prognostic Significance, and Paradigms for Reducing Risk , 2007, Clinical cardiology.

[163]  P. Gleason,et al.  Elevation of Hepatic Transaminases after Enoxaparin Use: Case Report and Review of Unfractionated and Low‐Molecular‐Weight Heparin‐Induced Hepatotoxicity , 2001, Pharmacotherapy.

[164]  D. Hawkins,et al.  Minimising the risk of heparin-induced osteoporosis during pregnancy , 2005, Expert opinion on drug safety.

[165]  A. James,et al.  Bone density changes in women who receive thromboprophylaxis in pregnancy. , 2005, American journal of obstetrics and gynecology.

[166]  B. Mulloy The specificity of interactions between proteins and sulfated polysaccharides. , 2005, Anais da Academia Brasileira de Ciencias.

[167]  E. Gabazza,et al.  Aberrations of the Tissue Factor Pathway in Patients Positive for Lupus Anticoagulant , 1999, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[168]  L. Śliwiński,et al.  Effects of standard heparin and low-molecular-weight heparins on the formation of murine osteoclasts in vitro. , 2005, Pharmacological reports : PR.

[169]  P. Ejstrud,et al.  Dose Relation in the Prevention of Proximal Vein Thrombosis with a Low Molecular Weight Heparin (Tinzaparin) in Elective Hip Arthroplasty , 2000, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[170]  J. Hallett Randomized trial of subcutaneous low-molecular weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism: Théry C, Simonneau G, Meyer G, et al. Circulation 1992; 85: 1380–1389 , 1993 .

[171]  W. Weitschies,et al.  Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. , 2008, Thrombosis research.

[172]  B. Chong,et al.  Heparin-induced thrombocytopenia associated with fondaparinux. , 2007, The New England journal of medicine.

[173]  A. Ekkernkamp,et al.  Thromboseprophylaxe in unfallchirurgischen Abteilungen in Deutschland , 2009, Der Unfallchirurg.

[174]  A. Turpie,et al.  A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. , 1999, The New England journal of medicine.

[175]  Y.‐Y. Wang,et al.  Enoxaparin‐induced alopecia in patients with cerebral venous thrombosis , 2006, Journal of clinical pharmacy and therapeutics.

[176]  Sundeep Khosla,et al.  The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[177]  M. O’Donnell,et al.  Major Bleeding, Mortality, and Efficacy of Fondaparinux in Venous Thromboembolism Prevention Trials , 2009, Circulation.

[178]  E. Antman,et al.  Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. , 2007, European heart journal.

[179]  A. Lincoff,et al.  Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[180]  L. Rauova,et al.  Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. , 2006, Blood.

[181]  T. Ittermann,et al.  Heparin‐induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests , 2010, Journal of thrombosis and haemostasis : JTH.

[182]  I. Gouin-Thibault,et al.  A need for evidence-based clinical practice guidelines for the use of heparins in the elderly , 2010, Clinical interventions in aging.

[183]  M. Torres,et al.  Lymphocyte proliferation response in patients with delayed hypersensitivity reactions to heparins , 2009, The British journal of dermatology.

[184]  J. Bassand,et al.  Impact of anaemia, bleeding, and transfusions in acute coronary syndromes: a shift in the paradigm. , 2007, European heart journal.

[185]  M. Kaplan,et al.  Evaluation of abnormal liver-enzyme results in asymptomatic patients. , 2000, The New England journal of medicine.

[186]  A. Trouvin,et al.  Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss , 2010, Clinical interventions in aging.

[187]  H. Kleinman,et al.  Heparanase regulates murine hair growth. , 2005, The American journal of pathology.

[188]  G. Lip,et al.  Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. , 2009, Chest.

[189]  H. Riess,et al.  A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study , 2010, Journal of thrombosis and haemostasis : JTH.

[190]  G. Raskob,et al.  Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. , 2003, Chest.

[191]  S. Gates,et al.  Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. , 2014, The Cochrane database of systematic reviews.

[192]  E. H. Terzi,et al.  The preventive effect of low molecular weight heparin on CCL₄-induced necrosis and apoptosis in rat liver. , 2010, Annals of hepatology.

[193]  S. Laporte,et al.  Meta‐analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery , 2001, The British journal of surgery.

[194]  A. Trautmann,et al.  Management of allergy to heparins in postoperative care: subcutaneous allergy and intravenous tolerance. , 2008, Dermatology online journal.

[195]  C. Chapelle,et al.  Thrombin generation and heparin‐induced thrombocytopenia , 2009, Journal of thrombosis and haemostasis : JTH.

[196]  Y. Gruel,et al.  Prospective evaluation of the ‘4Ts’ score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin‐induced thrombocytopenia , 2007, Journal of thrombosis and haemostasis : JTH.

[197]  M. Milling,et al.  Heparin-induced skin necrosis and low molecular weight heparins. , 1999, Annals of the Royal College of Surgeons of England.

[198]  A. Greinacher,et al.  Heparin-Induced Thrombocytopenia: Frequency and Pathogenesis , 2006, Pathophysiology of Haemostasis and Thrombosis.

[199]  A. Trautmann,et al.  Heparin allergy: delayed-type non-IgE-mediated allergic hypersensitivity to subcutaneous heparin injection. , 2009, Immunology and allergy clinics of North America.

[200]  M. Schindewolf,et al.  Incidence and causes of heparin-induced skin lesions , 2009, Canadian Medical Association Journal.

[201]  L. Śliwiński,et al.  Effects of heparin and low-molecular-weight heparins on bone mechanical properties in rats , 2004, Thrombosis and Haemostasis.

[202]  A. Greinacher,et al.  [Thrombosis prophylaxis in trauma surgery units in Germany: a survey]. , 2009, Der Unfallchirurg.

[203]  J. Kelton,et al.  Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? , 2005, The Journal of laboratory and clinical medicine.

[204]  J. Amiral,et al.  Platelet Factor 4 Complexed to Heparin Is the Target for Antibodies Generated in Heparin-Induced Thrombocytopenia , 1992, Thrombosis and Haemostasis.

[205]  Sunil V. Rao,et al.  Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group. , 2009, American heart journal.

[206]  J. Douketis,et al.  Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. , 2004, Chest.

[207]  N. Weissman,et al.  Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. , 2003, The American journal of cardiology.

[208]  A. Greinacher,et al.  Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. , 2002, Chest.

[209]  S. Yusuf,et al.  Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. , 2008, European heart journal.

[210]  J. Kelton,et al.  Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. , 2005, Blood.

[211]  M. Prins,et al.  Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. , 2010, The Cochrane database of systematic reviews.